Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03578783 · ClinicalTrials.gov registry record · Phase 2

PSD502 in Subjects With Premature Ejaculation

A Phase 2 study, sponsored by Plethora Solutions.

Completed
Registry status
Phase 2
Development phase
121
Enrollment target

NCT03578783: Completed Phase 2 study, sponsored by Plethora Solutions.

NCT03578783 is a Phase 2 study that has completed, run by Plethora Solutions. The registered enrollment target is 121 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03578783, a Phase 2 study, has completed, sponsored by Plethora Solutions.

COMPLETED
Registry status
Phase 2
Development phase
121 participants
Enrollment target

Study Summary

This study is being done to test the effect of PSD502 (the study medication) compared to placebo in subjects with premature ejaculation. PSD502 is a topical (applied to skin) anesthetic spray containing a mixture of two drugs called lidocaine and prilocaine that will be applied to the penis. Half of the subjects will receive PSD502 and half will receive placebo.

Interventions

  • DRUG Placebo
  • DRUG PSD502

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2018-12-26
Est. Completion 2021-12-01
Phase Phase 2

Sponsor

Plethora Solutions

3 total trials

What the Registry Record Tells You About NCT03578783

The ClinicalTrials.gov registry entry for NCT03578783 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Plethora Solutions, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03578783 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03578783 about?

NCT03578783 is a clinical study titled "PSD502 in Subjects With Premature Ejaculation". This study is being done to test the effect of PSD502 (the study medication) compared to placebo in subjects with premature ejaculation. PSD502 is a topical (applied to skin) anesthetic spray containing a mixture of two drugs called lidocaine and prilocaine that will be applied to the penis. Half of...

What is the current status of trial NCT03578783?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2018-12-26. Estimated completion is 2021-12-01.

What interventions are being tested in trial NCT03578783?

The interventions under investigation include: Placebo (DRUG), PSD502 (DRUG).

Who is sponsoring clinical trial NCT03578783?

This trial is sponsored by Plethora Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.